<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0028-3746</journal-id>
<journal-title><![CDATA[Neumología y cirugía de tórax]]></journal-title>
<abbrev-journal-title><![CDATA[Neumol. cir. torax]]></abbrev-journal-title>
<issn>0028-3746</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Neumología y Cirugía de Tórax; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas; Sociedad Cubana de Neumología; Sociedad Paraguaya de Neumología; Sociedad Boliviana de Neumología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0028-37462023000400220</article-id>
<article-id pub-id-type="doi">10.35366/117938</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consideraciones históricas del tratamiento médico de la tuberculosis]]></article-title>
<article-title xml:lang="en"><![CDATA[Historical considerations about of tuberculosis treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Lezama]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>82</volume>
<numero>4</numero>
<fpage>220</fpage>
<lpage>224</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0028-37462023000400220&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0028-37462023000400220&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0028-37462023000400220&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: A pesar de que la tuberculosis es tan antigua como la humanidad, su tratamiento médico inició en los años 40 con el descubrimiento de la estreptomicina. Este descubrimiento causó gran expectativa; sin embargo, poco después se notó que los pacientes que la recibían morían igual que los que no. Lo anterior dio paso al tratamiento con múltiples fármacos debido a la naturaleza de crecimiento de M. Tuberculosis. Múltiples tratamientos se han dado desde entonces, participando varias organizaciones a nivel mundial. Debido a la naturaleza cambiante de la micobacteria a causa de tratamientos ineficaces o dosis insuficientes, la lucha contra esta bacteria ha sido larga por la aparición de la monorresistencia, la polirresistencia, evolucionando hasta hoy a la llamada resistencia extendida. Todas las investigaciones actuales se encaminan a mejores pruebas diagnósticas y de tratamientos que acorten la duración del mismo. En este artículo se hace una revisión de la historia del tratamiento médico de la tuberculosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Although tuberculosis is as old as humanity, its medical treatment began in the 1940&#8217;s with the discovery of streptomycin. This discovery caused great expectation; However, shortly after it was noticed that patients who received it died just as well as those who did not. This gave way to treatment with multiple drugs due to the growth nature of M. Tuberculosis. Multiple treatments have been given since then, with various organizations worldwide participating. Due to the changing nature of the mycobacteria due to ineffective treatments or insufficient doses, the fight against this bacteria has been long, due to the appearance of monoresistance, polyresistance, evolving until today to the so-called extended resistance. All current research is aimed at better diagnostic tests and treatments that shorten its duration. This article reviews the history of medical treatment of tuberculosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="es"><![CDATA[multidrogorresistencia]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="en"><![CDATA[tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[Mycobacterium tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[multidrug resistant]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Medical Research Council</collab>
<article-title xml:lang=""><![CDATA[Streptomycin treatment of pulmonary tuberculosis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1948</year>
<volume>2</volume>
<numero>4582</numero>
<issue>4582</issue>
<page-range>769-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sutherland]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council]]></article-title>
<source><![CDATA[Q J Med]]></source>
<year>1954</year>
<volume>23</volume>
<numero>91</numero>
<issue>91</issue>
<page-range>347-66</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid; a Medical Research Council investigation]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1950</year>
<volume>2</volume>
<numero>4688</numero>
<issue>4688</issue>
<page-range>1073-85</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee]]></article-title>
<source><![CDATA[Br Med J]]></source>
<year>1952</year>
<volume>2</volume>
<numero>4787</numero>
<issue>4787</issue>
<page-range>735-46</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crofton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy of pulmonary tuberculosis]]></article-title>
<source><![CDATA[Br Med J]]></source>
<year>1959</year>
<volume>1</volume>
<numero>5138</numero>
<issue>5138</issue>
<page-range>1610-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<collab>International Union Against Tuberculosis</collab>
<article-title xml:lang=""><![CDATA[An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis]]></article-title>
<source><![CDATA[Bull Int Union Tuberc]]></source>
<year>1964</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>83-191</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-fifth investigation</collab>
<article-title xml:lang=""><![CDATA[A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1970</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>123-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Tuberculosis Chemotherapy Centre</collab>
<article-title xml:lang=""><![CDATA[A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>1959</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>51-144</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCune]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Tompsett]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug]]></article-title>
<source><![CDATA[J Exp Med]]></source>
<year>1956</year>
<volume>104</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>763-802</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1972</year>
<volume>1</volume>
<numero>7760</numero>
<issue>7760</issue>
<page-range>1079-85</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<collab>Third East African/British Medical Research Council Study</collab>
<article-title xml:lang=""><![CDATA[Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1980</year>
<volume>61</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>59-69</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<collab>Second East African/British Medical Research Council Study</collab>
<article-title xml:lang=""><![CDATA[Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1976</year>
<volume>114</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>471-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<collab>Hong Kong Chest Service/British Medical Research Council</collab>
<article-title xml:lang=""><![CDATA[Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, 3× weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1991</year>
<volume>143</volume>
<page-range>700-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchison]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The action of antituberculosis drugs in short course chemotherapy]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1985</year>
<volume>66</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-25</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jindani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nunn]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Enarson]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2004</year>
<volume>364</volume>
<numero>9441</numero>
<issue>9441</issue>
<page-range>1244-51</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bjarveit]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The tuberculosis situation in Norway]]></article-title>
<source><![CDATA[Scand J Respir Dis]]></source>
<year>1978</year>
<volume>102</volume>
<page-range>28-35</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakielna]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Cragg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Grzybowski]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lifelong follow up of inactive tuberculosis: its value and limitations]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1975</year>
<volume>112</volume>
<page-range>765-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enarson]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tuberculosis control in low-income countries]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Reichman]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Hershfield]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<source><![CDATA[Tuberculosis. A comprehensive international approach]]></source>
<year>2000</year>
<edition>2da</edition>
<page-range>55-71</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Marcel Dekker]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farga]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La conquista de la tuberculosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Farga]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Tuberculosis]]></source>
<year>2011</year>
<edition>3ra</edition>
<page-range>3-13</page-range><publisher-loc><![CDATA[Chile ]]></publisher-loc>
<publisher-name><![CDATA[Mediterráneo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ellard]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchison]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis units, 1946-1986, with relevant subsequent publications]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>1999</year>
<volume>3</volume>
<numero>10^s2</numero>
<issue>10^s2</issue>
<supplement>2</supplement>
<page-range>S231-79</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The current status of short course of chemotherapy]]></article-title>
<source><![CDATA[Tubercle]]></source>
<year>1979</year>
<volume>60</volume>
<page-range>177-90</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Who tuberculosis program; framework for effective control]]></source>
<year>1994</year>
<page-range>179</page-range><publisher-name><![CDATA[WHO/TB]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pablos-Méndez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raviglione]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Lazlo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Binkin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rieder]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Bustreo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global surveillance for antituberculosis drug resistance. 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>338</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1641-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espinal]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Laszlo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Simonsen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boulahbal]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Renero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>344</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1294-303</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<source><![CDATA[Anti-tuberculosis drug resistance in the world: fourth global report]]></source>
<year>2008</year>
<page-range>394</page-range><publisher-name><![CDATA[WHO/HTM/TB/]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<source><![CDATA[WHO/International Union against Tuberculosis Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world]]></source>
<year>1997</year>
<page-range>229</page-range><publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granich]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Balandrano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Santaella]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Binkin]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez- Fiol]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survey of drug resistance of Mycobacterium tuberculosis in 3 Mexican states, 1997]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2000</year>
<volume>160</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>639-44</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ait-Khaled]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Armengol]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bissel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Boillot]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caminero]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Management of tuberculosis: A guide to the essentials of good practice]]></source>
<year>2010</year>
<publisher-loc><![CDATA[Paris, France ]]></publisher-loc>
<publisher-name><![CDATA[International Union Against Tuberculosis and Lung Diseases]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Treatment of tuberculosis: guidelines]]></source>
<year>2010</year>
<edition>4th</edition>
<publisher-loc><![CDATA[Geneva, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Guidelines for treatment of drug susceptible tuberculosis and patient care. WHO/HTM/TB/2017.05]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Geneva, Switzerland ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Meghji]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Squire]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2018</year>
<volume>22</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1127-34</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Floyd]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Portocarrero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rapiti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<numero>9322</numero>
<issue>9322</issue>
<page-range>1980-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goble]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Iseman]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Waite]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Horseburgh]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>328</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>527-32</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Deun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid Salim]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar Das]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Bastian]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Portaels]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh]]></article-title>
<source><![CDATA[Int J Tuberc Lung Dis]]></source>
<year>2004</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>560-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Deun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maug]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Salim]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Sarker]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Daru]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rieder]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2010</year>
<volume>182</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>684-92</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunn]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rusen]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Van Deun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torrea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial]]></article-title>
<source><![CDATA[Trials]]></source>
<year>2014</year>
<volume>15</volume>
<page-range>353</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodall]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Meredith]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Nunn]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bayissa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatnagar]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Bronson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2022</year>
<volume>400</volume>
<numero>10366</numero>
<issue>10366</issue>
<page-range>1858-68</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diacon]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Pym]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grobusch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patientia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rustomjee]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Page-Shipp]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diarylquinoline TMC207 for multidrug-resistant tuberculosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>360</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2397-405</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gler]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Skripconoka]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez-Garavito]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera-Rivero]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas-Vasquez]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delamanid for multidrug-resistant pulmonary tuberculosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2151-60</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diacon]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[du Bois]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Narunsky]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Venter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Donald]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase II dose-ranging trial of the early bactericidal activity of PA-824]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2012</year>
<volume>56</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>3027-31</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palomino]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is repositioning of drugs a viable alternative in the treatment of tuberculosis?]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2013</year>
<volume>68</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>275-83</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conradie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Diacon]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Ngubane]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Everitt]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Crook]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of highly drug-resistant pulmonary tuberculosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>893-902</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conradie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bagdasaryan]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Borisov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mikiashvili]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ngubane]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>387</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>810-23</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="book">
<source><![CDATA[WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
